You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

List of Excipients in API MIDAZOLAM HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing MIDAZOLAM HYDROCHLORIDE

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Meridian Medical Technologies LLC SEIZALAM midazolam hydrochloride 11704-650 BENZYL ALCOHOL
Meridian Medical Technologies LLC SEIZALAM midazolam hydrochloride 11704-650 EDETATE DISODIUM
Meridian Medical Technologies LLC SEIZALAM midazolam hydrochloride 11704-650 HYDROCHLORIC ACID
Meridian Medical Technologies LLC SEIZALAM midazolam hydrochloride 11704-650 SODIUM CHLORIDE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Sign Up

Excipients in ANDA-approved (generic) drugs containing MIDAZOLAM HYDROCHLORIDE

Company Ingredient NDC Excipient
Hikma Pharmaceuticals USA Inc midazolam hydrochloride 0054-3566 ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc midazolam hydrochloride 0054-3566 D&C RED NO. 33
Hikma Pharmaceuticals USA Inc midazolam hydrochloride 0054-3566 EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc midazolam hydrochloride 0054-3566 GLYCERIN
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Sign Up

Detailed excipient profiles for MIDAZOLAM HYDROCHLORIDE

Excipient focus: ANHYDROUS CITRIC ACID

Excipient focus: BENZYL ALCOHOL

Excipient focus: CHERRY

Excipient focus: CITRIC ACID MONOHYDRATE

Excipient focus: D&C RED NO. 33

Excipient focus: EDETATE DISODIUM

Excipient focus: GLYCERIN

Excipient focus: HYDROCHLORIC ACID

Excipient focus: SACCHARIN SODIUM

Excipient focus: SACCHARIN SODIUM DIHYDRATE

Excipient focus: SODIUM BENZOATE

Excipient focus: SODIUM CHLORIDE

Excipient focus: SODIUM CITRATE

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SORBITOL

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group